Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal and heparin-treated antiphospholipid syndrome pregnancies

Lupus

Volumn 11, Issue 1, 2002, Pages 11-20

  Donohoe, S ^a   Mackie, I ^a   Machin, S ^a   Quenby, S ^b   Farquharson, R ^b   Panal, G ^c   Kingdom, J ^c   Malia, R ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibody; Coagulation activation markers; Heparin; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7A; CARDIOLIPIN ANTIBODY; DALTEPARIN; HEPARIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ANTIBODY TITER; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HEPARINIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION; COHORT STUDIES; FACTOR VIIA; FACTOR XIIA; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPARIN; HUMANS; LIPIDS; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROTHROMBIN;

EID: 0036182182     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu132oa     Document Type: Article

References (41)

1. The management of thrombosis in the antiphospholipid-antibody syndrome
2. Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism
3. Antiphospholipid antibodies and venous thromboembolism
4. Thrombin regulation in mother and fetus during pregnancy
5. Haemostasis in normal pregnancy
6. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy
7. Thrombophilia in pregnancy
8. Affinity purified human antiphospholipid antibodies bind normal term placenta
9. Ontogeny of beta 2 glycoprotein I and annexin V in villous placenta of normal and antiphospholipid syndrome pregnancies
10. Immunolocalisation of TFPI in placental tissue during normal and APS pregnancies
11. Risk of coronary heart disease and activation of factor XII in middle-aged men
12. Levels of activated FXII in survivors of myocardial infarction - Association with circulating risk factors and extent of coronary artery disease
13. The increased rate of activation of factor XII in late pregnancy can contribute to the increased reactivity of factor VII
14. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
15. The activation of the contact phase of coagulation by physiologic surfaces in plasma: The effect of large negatively charged liposomal vesicles
16. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of large triglyceride-rich lipoproteins
17. Syndrome of the black swan
18. Guidelines on the investigation and management of the antiphospholipid syndrome
19. Special report. The second international anti-cardiolipin standardization workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group
20. Anti-prothrombin antibodies: Assay conditions and clinical associations in the antiphospholipid syndrome
21. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome
22. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively defcient in promoting factor VII activation
23. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium
24. Influence of long term oral anticoagulants upon prothrombin fragment 1+2, thrombin-antithrombin III complex and D-Dimer levels in patients affected by proximal deep vein thrombosis
25. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
26. Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders
27. Downregulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome
28. Marked variation in antiphospholipid antibodies during pregnancy: Relationships to pregnancy outcome
29. 2GPI in association with other plasma constituents
30. 2 Glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases
31. Cytokines and immune-endocrine factors in recurrent miscarriage
32. A fresh look at the causes and treatments of recurrent miscarriage, especially its immunological aspects
33. Trends in immunoglobulin G anticardiolipin antibodies in ten successful heparin-treated pregnancies
34. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
35. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies
36. Placental pathologic features of preterm preeclampsia
37. Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome
38. Longitudinal study on activated factors XII and VII levels during normal pregnancy
39. Cl-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia
40. Increased FXII activation in patients with the antiphospholipid syndrome
41. Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies